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Infection of host cells with human cytomegalovirus (HCMV) induces cell cycle dysregulation. Two HCMV
immediate-early (IE) proteins, IE1-72 and IE2-86, are promiscuous transactivators that have been implicated
in the dysregulatory events. Cellular p53 protein is accumulated to high levels in HCMV-infected cells, but the
indicative marker of p53 transcriptional activity, p21, is markedly decreased. Both IE1-72 and IE2-86 were able
to transactivate the p53 promoter and interact with p53 protein in DNA-transfected or HCMV-infected cells.
HCMV UL84, a multiregulatory protein expressed in early periods of HCMV infection, also interacted with
p53. HCMV IE1-72 prevented or disrupted p53 binding to p53-specific DNA sequences, while IE2-86 and/or
UL84 enhanced p53 binding and induced supershift of this DNA-protein complex. Both HCMV IE1-72 and
IE2-86 were able to inhibit p53-dependent transcriptional activation in plasmid-transfected cells. IE1-72,
rather than IE2-86, was found to be responsible for p21 downregulation in HCMV-infected HEL cells. DNA
transfection analysis using IE1-72 mutants revealed that exon 2/3 and the zinc finger region of IE1-72 are
essential for IE1-72’s effect on the repression of p53-dependent transcriptional activation. These data suggest
that HCMV IE1-72 and/or IE2-86 transactivates the p53 promoter and induces p53 accumulation, but HCMV
IE1-72 represses the p53 transactivation activity by a unique binding hindrance mechanism different from that
of IE2-86. Thus, various modes of viral IE proteins and p53 interactions might result in multiple outcomes,
such as stimulation of cellular DNA synthesis, cell cycle progression and cell cycle arrest, and prevention of
program cell death.
Human cytomegalovirus (HCMV), a member of the herpes-
virus family, is the leading viral cause of birth defects and poses
a serious threat in immunocompromised patients and in organ
transplant recipients (35, 43). One of the distinctive features of
HCMV is that it affects many aspects of host cell regulation
and metabolism, including stimulation of the synthesis of cel-
lular DNA, RNA, and proteins (16, 53). In productive infec-
tion, HCMV gene expression occurs in three temporally reg-
ulated phases, termed the immediate-early (IE), early, and late
phases (53, 73). The IE proteins IE1-72 and IE2-86 are alter-
natively spliced gene products of the major IE gene that play
important roles in the regulation of viral and cellular gene
expression. Expression of HCMV IE1-72 and IE2-86 alters the
cell cycle to generate an environment conducive to stimulating
quiescent cells to enter G1/S phase (82), arresting cell cycle
progression (45), inducing cellular macromolecule synthesis (7,
8), and resisting apoptotic stimuli (83).
IE1-72 has been shown to be a strong activator of the major
IE promoter and can stimulate transcription of many viral and
cellular promoters (12, 14, 27, 68, 77). Expression of IE1-72
also induces p53 accumulation in infected fibroblasts, resulting
in the alteration of cell cycle control (8).
IE2-86 protein has been identified as an essential promiscu-
ous transcriptional transactivator and repressor molecule that
autoregulates IE gene expression by binding to cis repression
signal sequences of the major IE promoter (11, 58, 59). Studies
have demonstrated an interaction between HCMV IE2-86 and
cellular p53 that correlates with HCMV infection and coronary
restenosis (66, 67). Expression of IE2-86 also induces p53
accumulation in fibroblasts (8, 54, 55), resulting in cellular
proliferation (8). IE2-86 has been shown to interact with p53 in
vitro and in vivo (3, 66, 70), and this interaction results in the
downregulation of p53’s transactivation function (66, 70). IE2-
86, but not IE1-72, increases the half-life of p53 and reduces
that of mdm2 (80). There has been no report of direct binding
of IE1-72 to p53. The exact nature of the interaction between
IE proteins and p53 remains to be elucidated.
Cellular protein p53 has been known as a tumor suppressor
gene product (17, 31, 42) and cell cycle inhibitor (48). It is
known to regulate transcription of a variety of genes, including
genes involved in cell cycle regulation, DNA repair, and pro-
grammed cell death (28, 52, 62). Elevated levels of p53 were
observed in cell lines transformed by a variety of agents, in-
cluding DNA and RNA tumor viruses, and chemical carcino-
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gens (for reviews, see reference 61). Although several studies
have shown that p53 levels are rapidly active and stabilized
after HCMV infection in several cell types (36, 44, 55, 67),
there is no significant activation of p53 downstream targets (4,
36). On the other hand, p53 appears to play some functional
roles in the life cycle of HCMV. It was shown that p53 was
involved in the regulation of viral UL94 protein expression
(75). Fortunato and her colleagues demonstrated that cells
infected with HCMV in the absence of p53 (p53/ HF cells)
produced fewer infectious viral particles (5). Viral protein pro-
duction, trafficking, and viral encapsidation delays were found
in cells lacking p53. By microarray analyses, Fortunato’s group
further revealed that expression of 22 viral genes was affected
by the absence of p53, and the presence of p53 is important for
both IE and early viral gene expression mostly at IE and early
times postinfection (28). These influences are probably due to
the combination of direct and indirect interaction of p53 with
the virus proteins and genome (28).
Our study here was originally designed to assess the hypoth-
esis that p53 controls the initiation of viral DNA replication by
binding to a p53-specific DNA binding site located within the
origin of HCMV DNA replication (oriLyt), and the expression
of HCMV IE1-72 protein will allow the removal of p53 from
oriLyt or from a IE1-72/p53 complex to facilitate the initiation
of HCMV DNA replication. Therefore, this study was per-
formed first to investigate the effect of IE1-72 and IE2-86 on
p53 promoter activity and on the sequence-specific binding
activity of p53, as well as to define the regions of IE1-72 that
mediate its effect on p53. Although IE1-72 and IE2-86 exerted
similar transcriptional repression effects on a p53-responsive
promoter, their mechanisms of repression were different.
IE1-72 disrupted p53 binding to its DNA-specific binding se-
quences while IE2-86 enhanced this binding. Whether the
binding of IE1-72 disrupts p53 binding to its DNA-specific
binding sequences will facilitate the initiation of HCMV DNA
replication has to be further investigated.
MATERIALS AND METHODS
Cell culture and virus. Human embryonic lung (HEL-299; ATCC CCL137)
cells and a human osteosarcoma cell line, Saos-2 (ATCC HTB-85), were prop-
agated in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS; Gibco-BRL, Gaithersburg, MD) and penicillin-
streptomycin at 37°C in a 6% CO2 incubator. Infection with the HCMV Towne
strain (P-34; gift of Stanley Plotkin) was performed as described previously (33).
A multiplicity of infection (MOI) of 2 to 5 was used for all experiments. Cells and
virus were incubated for 90 min at 37°C in a 6% CO2 incubator. Unabsorbed free
virus was removed, and DMEM with 4% heat-inactivated FBS was added to the
infected culture.
Plasmids. The IE1-72, IE2-86, and UL84 eukaryotic expression vectors
(pcDNA3IE1-72, pcDNA3IE2-86, and pcDNA3UL84) and prokaryotic expres-
sion vectors (pGEX-IE1-72, pGEX2T-IE2-86, and pGEX2T-UL84) were de-
scribed previously (21, 30, 60, 78). The IE1-72 full-length and mutant expression
vectors (pSG5IE1, pSG5IE1exon2/3, pSG5IE1exon3, pSG5IE1LZ,
pSG5IE1acidic, pSG5IE1ZF, and pSG5IE1350-420) were gifts from J. Sinclair
and have been described elsewhere (29, 60, 78). The p53-responsive reporter
constructs, pG13CAT (where CAT is chloramphenicol acetyltransferase) for the
wild type and MG15CAT for the mutant, were gifts from B. Vogelstein and were
described previously (38, 79). The p53 expression plasmids, pC53-SN3 for wild-
type p53 and pC53-SCX3 for mutant p53, were also gifts from B. Vogelstein and
were as described previously (2). Recombinant His-tagged p53 protein was
expressed in baculovirus as described previously (2). The p53 promoter-CAT
construct (wild type) was a gift from Shannon Kenney. This promoter has a
600-bp insert obtained by PCR from the human endothelial cell p53 promoter
region using the sequences identified by Tuck and Crawford (71).
Antibodies. Monoclonal antibodies to p53, DO-1 (Santa Cruz Biotechnology,
Santa Cruz, CA) and Ab-4 (CalBiochem, La Jolla, CA), were used. Antibodies
to IE1-72, IE2-86, and UL84 were generated in our laboratory as described
previously (30, 39).
Protein expression. Recombinant p53 protein was produced in SF21 insect
cells and purified as described previously (20). The IE1-72, IE2-86, and UL84
glutathione S-transferase (GST) fusion proteins, GST-IE1-72, GST-IE2-86, and
GST-UL84, were propagated and purified as described previously (21). Briefly,
GST fusion proteins were purified from corresponding plasmid-transfected Esch-
erichia coli BL21 bacterial lysates by loading to glutathione-Sepharose 4B col-
umns (Pharmacia Biotech, Piscataway, NJ) after clarification by centrifugation.
The fusion protein-loaded columns were washed five times with 5 volumes of an
ice-cold phosphate-buffered saline (PBS) with 1% Triton X-100 (Sigma, St.
Louis, MO). The GST fusion proteins were then eluted with 20 mM reduced
glutathione (Boehringer Mannheim Corporation, Indianapolis, IN) in 100 mM
Tris-HCl (pH 8.0) solution, dialyzed, and stored at 70°C until used.
Immunoprecipitation. Approximately 200 g of HCMV-infected cell lysate
was precleared for 1 h with Pansorbin cells (CalBiochem, La Jolla, CA). Mono-
clonal antibody and 30 l of protein G beads (Pharmacia, Uppsala, Sweden)
were added, and the volume was increased to 0.5 ml with ELB buffer (0.25 M
NaCl, 0.1% Nonidet P-40, 0.05 M HEPES [pH 7.0], 1 mM phenylmethylsulfonyl
fluoride, 5 mM EDTA, 0.5 mM dithiothreitol). The incubation was performed at
4°C for 4 h with constant mixing. Beads were spun down and washed six times
with ELB buffer. The beads were mixed with Laemmli sodium dodecyl sulfate
(SDS) sample buffer and boiled. Supernatant was run on SDS-polyacrylamide gel
electrophoresis gels. Western blot analysis was used to detect proteins in the
immunoprecipitated complexes by the appropriate antibody.
p53 EMSA. An electrophoretic mobility shift assay (EMSA) was performed as
described previously (78). In brief, baculovirus-expressed p53 protein alone or
together with various amounts of GST-IE1-72, GST-IE2-86, or GST-UL84 were
incubated in a binding buffer (10 mM Tris-HCl, 50 mM NaCl, 0.5 mM EDTA,
10% glycerol, 1 mM dithiothreitol) plus 7.5 mM MgCl2, 0.1 mg of poly(dI-dC)
(Pharmacia Biotech), and a 32P-labeled, wild-type p53 (5-CCTGCCTGGACT
TGCCTGG-3; two copies) or mutant p53 (5-CCTTAATGGACTTTAATGG-
3; two copies) double-stranded oligonucleotide probe for 15 min. The samples
were electrophoresed on a 5% polyacrylamide gel, vacuum dried, and subjected
to autoradiography using X-ray films with intensifier screens at 70°C. For
EMSAs in which the GST-IE1-72, GST-IE2-86, or GST-UL84 fusion protein was
added, equal protein amounts of the different fusion proteins and GST alone
were incubated in the above-mentioned reaction mixture. Titrations of the fusion
products and different incubation conditions were used to determine the optimal
conditions for these experiments.
Microarray. HEL cells were infected at an MOI of 4 per cell of HCMV. The
infected cells were harvested at 0, 6, 12, 24, 48, 72, and 96 h postinfection (hpi).
Total RNA was extracted from infected cells using Trizol (Invitrogen, Carlsbad,
CA) at each time point. Total RNA (2 g) was reverse transcribed with a
Chemiluminescent RT-IVT Labeling kit (Applied Biosystems, Foster City, CA)
and hybridized to the Human Genome Survey Microarray (Applied Biosystems).
For each time point, data were initially normalized, and differential gene expres-
sion at each time point was calculated by comparing the differences between
expression levels at each time point and the level in mock-infected HEL cells at
0 hpi.
IE1-72 and IE2-86 knockdown by siRNA. HCMV IE1-72 and IE2-86 were
knocked down in HEL cells after HCMV infection by small interfering RNAs
(siRNAs) as described previously (41, 80). In brief, the IE1-72 siRNA 5GGU
UAUCAGUGUAAUGAAGdTdT-3 and complement 5CUUCAUUACACU
GAUAACCdTdT-3 targeting HCMV IE1-72 as well as the IE2-86 siRNA
oligonucleotide 5-AAACGCAUCUCCGAGUUGGACdTdT-3 and comple-
ment 5-GUCCAACUUGGAGAUGCGUUUdTdT-3 targeting HCMV IE2-86
were synthesized by Dharmacon (Lafayette, CO) as described previously (74).
HEL cells were grown to confluence in 100-mm dishes at 37°C in an atmosphere
of 6% CO2 and serum starved for 24 h. Dishes of cells were transfected with 10
l of Lipofectamine 2000 and 5 l of 20 M siRNA, according to the manufac-
ture’s instructions (Invitrogen). Four hours later transfected cells were washed
twice with DMEM, and the medium was replaced with DMEM. At 24 h post-
transfection cells were infected with 2 to 5 PFU/cell of HCMV. The plates were
incubated for an additional 16 h prior to harvesting for Western blot analysis.
UV treatment of HEL cells. Nearly confluent HEL cell cultures (95 to 99%
confluence) were washed once with PBS. Cells were UV irradiated (30 mJ/cm2)
with UV cross-linker after PBS was removed, and DMEM was then added to
plates. UV-irradiated HEL cells were harvested 8 h post-UV treatment for
Western blot analysis.
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Western blot analysis. Equal protein amounts of lysates per time point were
mixed in Laemmli sample buffer and were loaded onto 10% SDS-polyacrylamide
gels. Proteins were separated by electrophoresis and transferred overnight at 18
V to Immobilon-P Transfer Membrane (Millipore, Bedford, MA) blots. The
blots were blocked for 1 h in 5% (wt/vol) nonfat dry milk dissolved in PBS. The
blots were then probed with primary antibody for 1 h in PBS and were washed
three times with PBS–0.1% Tween 20. After the washing step, the blots were
probed with secondary antibody(horseradish peroxidase-conjugated anti-mouse
immunoglobulin G; Sigma, St. Louis, MO). The blots were again washed exten-
sively in PBS–0.1% Tween 20 and then in PBS alone and subsequently were
developed by enhanced chemiluminescence (Amersham, Buckinghamshire, En-
gland) according to the manufacturer’s protocol.
CAT assay. For transfection and infection experiments, HEL cells were seeded
onto 100-mm-diameter plates at 1  106 cells. The following day, cells were
transfected with plasmid DNA via calcium phosphate-mediated transfection. For
each 100-mm-diameter plate, 1 g of p53 promoter-CAT plasmid along with 1
g of pCMV-Gal was mixed in a final volume of 500 l of HEPES-buffered
saline (50 mM HEPES, 280 mM NaCl, 10 mM KCl, 12 mM dextrose, 1.5 mM
Na2HPO4, pH 7.4) and 500 l of 0.25 M calcium chloride solution. The DNA-
calcium phosphate complexes were added dropwise to the cultured cells. All
transfections were done in triplicate and were allowed to proceed overnight. The
next day, the transfectant was removed, and cells were washed once with 10 ml
of DMEM. The cells were subsequently infected with HCMV at the MOIs shown
in Fig. 1B. Following a 90-min adsorption period, 10 ml of DMEM supplemented
with 4% heat-inactivated FBS was added to each 100-mm-diameter plate. Cells
were harvested at the appropriate time points postinfection in 250 l of 1 cell
lysis buffer (Promega, Madison, WI). For CAT assays, cell extract was mixed with
acetylenzyme coenzyme A (Boehringer Mannheim) and [14C]chloramphenicol
(New England Nuclear), and CAT assays were performed as described previ-
ously (24). Samples were standardized by using a Promega galactosidase enzyme
assay system as suggested by the manufacturer. Absorbance at 420 nm for each
sample was determined with a Beckman DU-70 spectrophotometer. In the ex-
periments using the cotransfection assay to study p53 promoter or p53-respon-
sive promoter activations, 1 g of the p53 promoter-CAT construct or p53-
responsive CAT construct (pG13CAT or pMG15CAT) and various IE1-72
wild-type or mutant plasmids were transfected into Saos-2 cells.
RESULTS
Kinetics of HCMV IE1-72, IE2-84, and UL84 protein ex-
pressions and the induction of the accumulation of p53 in
HCMV-infected HEL cells. The expression of HCMV IE1-72,
IE2-86, UL84, and p53 in HCMV-infected HEL cells was
determined at various time points postinfection by Western
blot analysis. IE1-72 and IE2-86 were detected as early as 4 hpi
(Fig. 1A, lanes 3 to 8), while UL84 was detected starting at 8
hpi (Fig. 1A, lanes 4 to 8). IE1-72 and IE2-86 levels steadily
increased throughout the infection time course. The amount of
UL84 increased at the early stage of viral DNA replication and
reached a plateau at 48 and 72 hpi. Increases in p53 were first
observed at 4 hpi; the protein levels were then increased in
parallel with both IE1-72 and IE2-86, reaching a plateau at
48 hpi.
HCMV IE proteins transcriptionally transactivate the p53
promoter. Using CAT assays on lysates from HCMV-infected
FIG. 1. Transactivation of p53 promoter by HCMV IE1-72 and IE2-86. (A) Western blots demonstrating expression of IE1-72, IE2-86, UL84,
and p53 in HCMV-infected HEL cells harvested and lysed at the times (hours postinfection) indicated. M, mock infected. (B) Results of CAT
assays demonstrating activation of p53 promoter in lysates from HEL cells harvested at the indicated times after HCMV infection. Bars indicate
standard deviations. (C) CAT assays from lysates of Saos-2 cells transfected with combinations of target promoter construct, p53 promoter-CAT,
and plasmids encoding wild-type p53, mutant p53 (p53mut), IE1-72, and IE2-86, as indicated. Values shown are means plus standard deviations
for three experiments, each run with triplicate samples. pcDNA3, transfection with empty plasmid.
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HEL cells, we determined that p53 promoter activity was en-
hanced by IE protein expression in a dose-dependent manner
(Fig. 1B). When HEL cells were first transfected with the
p53 promoter-CAT reporter plasmid and then infected with
HCMV 24 h later, p53 promoter activity was activated
throughout the entire HCMV infection course. There were
nearly 80- and 100-fold enhancements in p53 promoter-CAT
activity at 72 hpi with MOIs of 0.2 and 2, respectively. There
was only basal p53 promoter activity in mock-infected cells and
less than fivefold activation with pCAT (without p53 promoter
sequence) control transfection in HCMV-infected cells.
The role of IE1-72 and IE2-86 in p53 promoter activation
was analyzed by cotransfection of p53-deficient Saos-2 cells
with IE plasmids and wild-type (pC53-SN3) or mutant p53
(pC53-SCX3) expression vectors. CAT assays were then used
to determine p53 promoter activity (Fig. 1C) because the
Saos-2 cell line was p53/ (deletion of the p53 coding se-
quence in Saos-2 cell line was demonstrated previously by
Masuda et al. [49] and Scheffner et al. [64]), and the DNA
transfection efficiency is greater in Saos-2 than in HEL cells. In
Saos-2 cells, p53 promoter activity was activated approximately
threefold by the cotransfection with the wild-type human p53
expression vector but not by cotransfection with mutant p53,
which suggested that wild-type p53 activates its own promoter.
p53 promoter activity was activated only slightly by IE1-72 but
approximately eightfold by IE2-86. Cotransfection of cells with
IE1-72 and p53 together activated p53 promoter activity four-
to sixfold. While IE1-72 transactivated p53 promoter additively
with p53, a negative effect was found when IE2-86 and p53
were transfected together, with up to a 40% decrease in CAT
activity compared to IE2-86 alone. There was only basal CAT
activity in cells cotransfected with the pCAT control vector and
the various IE or p53 expression plasmids.
HCMV infection downregulates p53 downstream target gene
expression. mRNA expression levels of genes containing p53-
responsive elements p21, mdm2, and Bax were measured in
HCMV-infected HEL cells by human genomic microarray as-
say, and relative changes in expression are reported in Fig. 2.
The expression levels of all three of these p53-responsive genes
were decreased at least twofold compared with those in mock-
infected HEL cells between 6 to 96 hpi.
p53 interacts with IE1-72 and IE2-86 in HEL cells infected
with the Towne strain of HCMV. To examine the interaction
between HCMV IE proteins and p53, we performed immuno-
precipitation of lysates of HCMV-infected cells with anti-p53
antibody and immunoblotting with anti-IE1-72 or anti-IE2-86
antibody. IE1-72 and IE2-86 proteins coprecipitated with p53
in immunoprecipitation preparations from HCMV-infected ly-
sates collected at 12, 24, and 48 hpi (Fig. 3). p53-containing
complexes from mock-infected lysates did not contain the
IE1-72 and IE2-86 proteins (Fig. 3, 0 hpi).
Both HCMV IE1-72 and IE2-86 interact with HCMV UL84.
UL84 is an HCMV-specific phosphor-protein which is not only
associated with DNA polymerase but also carries UTPase ac-
tivity. It is required for oriLyt-dependent DNA replication and
virus growth (13, 22). When HCMV-infected HEL cell lysates
were immunoprecipitated with either anti-HCMV IE1-72 or
IE2-86 antibody and then immunoblotted with anti-UL84
antibody, UL84 was found to coprecipitate with either
IE1-72 or IE2-86 in lysates collected at 16 hpi and thereafter
(Fig. 4A). When lysates were immunoprecipitated with anti-
HCMV UL84 antibody and then immunoblotted with anti-
IE1-72 or anti-IE2-86 antibody, both IE1-72 and IE2-86 were
detected in immunoprecipitation products from lysates col-
lected at 6 hpi and thereafter (Fig. 4B). These results suggested
that both IE1-72 and IE2-86 interacted with UL84. To test if a
complex comprised of all three proteins, IE1-72, IE2-86 and
UL84, is formed in HCMV-infected cells, the lysates of
HCMV-infected HEL cells were immunoprecipitated first with
anti-IE2-86, and the supernatant from the first immunopre-
cipitation was subsequently immunoprecipitated with anti-UL84
antibody. The IE1-72 protein was detected in the anti-UL84
immunoprecipitation complex but not in the first anti-IE2-86
immunoprecipitation complex (Fig. 4C). These data indicate
FIG. 2. mRNA expression pattern of p53-responsive genes, p21,
mdm2, and Bax, in HEL cells infected with the Towne strain of
HCMV. mRNA levels of each gene were detected by microarray assay
as described in Materials and Methods. Values shown are the differ-
ences between those in HCMV- or mock-infected HEL cells at the
indicated time and in mock-infected HEL cells at 0 hpi.
FIG. 3. p53 interacts with HCMV IE1-72 and IE2-86 in HEL cells
infected with the Towne strain of HCMV. Western blots demonstrat-
ing immunoreactivity to IE1-72, IE2-86, or p53 in complexes immu-
noprecipitated (IP) with anti-p53 antibody from lysates of HEL cells
infected with HCMV and harvested at the indicated times postinfec-
tion.
VOL. 83, 2009 INTERACTIONS OF HCMV MAJOR IE PROTEINS AND p53 12391
that the bindings of IE1-72 and IE2-86 to UL84 are mutually
exclusive.
HCMV IE1-72 prevents p53 binding to p53-specific DNA
binding sequences while IE2-86 and/or UL84 is capable of
enhancing the ability of p53 to bind to p53-specific DNA se-
quences and inducing supershift. To assess the effect of IE1-72
on the binding of p53 to p53-specific binding sequences, an
EMSA was performed with recombinant p53 derived from
baculovirus (Bac-p53), prokaryotically expressed IEs and
UL84 proteins (GST fusion proteins), and a radioactively
labeled p53-specific oligonucleotide probe. EMSA results
showed that Bac-p53 bound specifically to p53 consensus se-
quences (Fig. 5) but not to a mutant p53 probe (Fig. 5D). GST,
GST-IE1, GST-IE2, or GST-UL84 alone could not bind to the
wild-type p53 DNA probe. When Bac-p53 was mixed with
GST-IE1-72, the degree of p53 binding to DNA probe was
decreased with increases in the amount of GST-IE1-72 (Fig.
5A, lanes 6 to 8). p53 binding to p53 wild-type probe was
almost completely disrupted in EMSAs when two times the
amount of GST-IE1 (0.35 g/reaction mixture) was mixed with
Bac-p53 (0.17 g/reaction mixture) (Fig. 5, lane 8). When
Bac-p53 was mixed with GST-IE2-86 (Fig. 5B, lanes 4 to 6) or
GST-UL84 (Fig. 5E, lanes 4 to 6), p53 DNA binding was
increased in a dose-dependent manner with the addition of
increasing amounts of GST-IE2-86 or GST-UL84. In view of
the fact that IE1-72, IE2-86, and UL84 are expressed during
the IE and early period in HCMV-infected cells (demonstrated
in Fig. 1A) and that IE1-72 and IE2-86 and UL84 exerted
different or opposite effects on p53 DNA binding activity, we
then performed an experiment to determine the effects of
various combinations of IE1-72 and of IE2-86 and UL84 si-
multaneously on p53 DNA binding activity, and the results are
shown in Fig. 5C and F. When fixed amounts of IE1-72 and p53
were used for EMSAs, increasing amounts of IE2-86 enhanced
p53 binding in a dose-dependent manner (Fig. 5C, lanes 6 to
8). On the other hand, when the amounts of input IE2-86 and
p53 were fixed, p53-DNA binding decreased or was disrupted
drastically with increases in the amount of input IE1-72 (Fig.
5C, lanes 9 and 10). IE2-86 and UL84, independently and in
combination, enhanced p53 binding in a dose-dependent fash-
ion (Fig. 5F, lanes 4 to 10), and increased enhancement was
observed when the input UL84 level was increased by two- or
threefold (Fig. 5F, lanes 9 and 10).
HCMV IE1-72, IE2-86, and UL84 proteins downregulate
p53-dependent transcriptional activation in Saos-2 cells. To
determine the effects of IE1-72, IE2-86, and UL84 on p53
transcriptional activation in eukaryotic cells, the CAT activities
were measured in p53-deficient Saos-2 cells following cotrans-
fection with wild-type or mutant p53-responsive CAT reporters
(pG13CAT or pMG15CAT) and various combinations of p53-,
UL84- and IE-expressing plasmids (Fig. 6). In control experi-
ments, wild-type p53 could not transactivate the mutant p53
reporter (Fig. 6B). Transfection with wild-type pG13CAT or
parental vector (pcDNA3) alone had no CAT activity. The
presence of mutant p53, IE1-72, or IE2-86 alone could not
transactivate pG13CAT. Additionally, the combination IE2-86
and IE1-72 did not significantly transactivate pG13CAT. On
the other hand, wild-type p53 alone activated the wild-type
pG13CAT reporter. When wild-type p53 plasmid was cotrans-
fected with IE1-72, IE2-86, or both IE1-72 and IE2-86 expres-
sion plasmids together, transcriptional activation activity of
p53 was suppressed by 70% (IE1-72), 81% (IE2-86), and 76%
(IE1-72 plus IE2-86), compared with transcriptional activation
activity of p53 alone (Fig. 6B).
The effects of UL84 in similar CAT experiments are sum-
marized in Fig. 6C. In cotransfection of the wild-type p53
plasmid with UL84 or IE2-86 alone or with UL84 and IE2-86
in combination, the transcriptional activation activity of p53
was suppressed by 87% (UL84 alone), 84% (IE2-86), and 95%
(UL84 plus IE2-86) compared to the transcriptional activation
activity of p53 alone.
HCMV IE1-72, rather than IE2-86, was responsible for p21
downregulation in IE1-72 and IE2-86 siRNA-treated HEL cells
infected with HCMV. Since p21 is a downstream target of p53,
we assessed the effect of HCMV IE1-72 and IE2-86 on p21
expression, as determined by levels of p21 measured by West-
B
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FIG. 4. Both HCMV IE1-72 and IE2-86 interacted with HCMV
pUL84. (A) Western blots demonstrating the presence of UL86 in
complexes immunoprecipitated with anti-IE2-86 (upper panel) and
anti-IE1-72 (lower panel) antibodies from lysates of HCMV-infected
cells harvested at the indicated times postinfection. (B) Western blots
(WB) demonstrating IE1-72 and IE2-86 immunoreactivity in com-
plexes immunoprecipitated (IP) with anti-HCMV UL84 antibody from
lysates of HCMV-infected HEL cells harvested at the indicated times
postinfection. (C) Lysates of HCMV-infected cells harvested at the
time indicated were immunoprecipitated first with anti-IE2 antibody,
and the supernatant was subsequently immunoprecipitated with anti-
UL84 antibody. Both immunoprecipitated complexes were subjected
to Western blotting to detect the presence of IE1-72 with anti-IE1
antibody. , anti; IgG, immunoglobulin G.
12392 HWANG ET AL. J. VIROL.
ern blot analysis. p21 was detected in confluent HEL cells (0
hpi) as well as in early stages of HCMV-infected HEL cells
(before 16 hpi) (Fig. 7A). However, the p21 protein level was
remarkably decreased and hardly detected at 24 hpi and there-
after. On the other hand, p53 expression was detected in
HCMV-infected HEL cells as early as 4 hpi and continuously
increased.
We then utilized an IE1-72 and IE2-86 siRNA knockdown
to study the role of HCMV IE proteins in the inhibition of p21
expression in HCMV-infected cells. Pretreatment of HEL cells
with IE2-86 and IE1-72 siRNA did not appear to alter baseline
p21 levels (Fig. 7B, lane 2, and C, lane 3, respectively). p21
expression was decreased at 16 hpi in HCMV-infected HEL
cells that were pretreated with IE2-86 siRNA (Fig. 7B, lane 5).
On the other hand, p21 expression was increased in HCMV-
infected HEL cells that were pretreated with IE1 siRNA (Fig.
7C, compare lane 6 to lanes 4 and 5). Lane 3 of Fig. 7B and
lane 7 of Fig. 7C are positive controls in which HEL cells were
treated with UV. The resulting data suggest that IE1-72, but
not 1E2-86, plays an important role in the decrease of p21
levels in HCMV-infected HEL cells.
Exon 2/3 and zinc finger domains of the HCMV IE1-72
protein are required for IE1-72 repression of p53-dependent
transcriptional activation. In order to determine the domains
of IE1-72 necessary for the suppression of p53 transcriptional
activity, we cotransfected Saos-2 cells with pG13CAT, wild-
type p53, and full-length IE1-72 or various deletion mutant
plasmids of IE1-72. Lysates of transfected cells were pre-
pared, and CAT activity was measured. Transfection of cells
with pG13CAT alone or with empty vector (pcDNA3) plus
FIG. 5. HCMV IE1-72 prevented p53 binding to p53-specific DNA binding sequences while IE2-86 and/or UL84 enhanced binding. EMSA was
performed after purified recombinant proteins were mixed, as indicated, in binding buffer containing 32P-labeled double-stranded oligonucleotide
probe, as described in Materials and Methods. The effect of increasing the amounts of these proteins alone or in various combinations on p53
binding to p53-specific DNA binding sequences is shown: IE1-72 (A), IE2-86 (B), IE1-72 plus IE2-86 (C), HCMV UL84 (E), and UL84 plus IE2-86
(F). Numbers in parentheses indicate ratios (wt/wt or wt/wt/wt) of proteins in the indicated reaction. Panel D shows the specific binding of p53 to
32P-labeled double-stranded wild-type (wt) p53 oligonucleotide probe and the inability of p53 to bind mutant probe (mt).
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pG13CAT revealed no CAT activity. pcDNA3IE1-72 with
pG13CAT had a basal level of CAT activity. Wild-type p53
increased activation of pG13CAT an average of 28-fold. Ad-
dition of full-length of IE1-72 to wild-type p53 in cotransfec-
tion resulted in a dramatic decrease in CAT activity, from
28-fold activation down to an average of 1.2-fold activation.
Cotransfection of wild-type p53 with mutant IE1-72s with de-
letions in exon 2/3, exon 3, the leucine zipper domain, the zinc
finger domain, residues 350 to 420, or the acidic domain
showed an average of 24.5-, 10.0-, 3.7-, 16.8-, 6.5-, and 5.0-fold
activation, respectively (Fig. 8). These data indicate that only a
mutation in exon 2/3 could lead to complete activation of p53,
in comparison with the suppressive effect of full-length IE1-72
on the transactivation of p53. Deletion mutants in exon 3 and
the zinc finger domain of IE1-72 led to partial restoration of
p53 activity. These results indicate that IE1-72 exon 2, exon 3,
FIG. 6. HCMV IE1-72, IE2-86, and UL84 downregulated p53-dependent gene transactivation in Saos-2 cells. (A) Diagram of target constructs
showing wild-type (pG13CAT) and mutant (pMG15CAT) CAT reporter plasmids. WT* PRE, wild-type p53 responsive element with 13 copies of
5-CCTGCCTGGACTTGCCTGG-3 in plasmid pG13CAT (also called pSK-45-13-2-PyCAT); MUT* PRE, mutant PRE with 15 copies of
5-CCTTAATGGACTTTAATGG-3 in plasmid pMG15CAT (also called pSK89-15-1-PyCAT). (B and C) CAT assays of lysates from p53-
negative Saos-2 cells cotransfected with combinations of expression vectors for IE1-72 and IE2-86 (B) and for IE2-86 and UL84 (C), along with
wild-type p53 (p53WT) or mutant p53 (p53mut), as indicated, and with expression vectors for the target reporter constructs described in panel A,
as indicated.
FIG. 7. IE1-72 rather than IE2-86 was responsible for p21 downregulation in IE2-86 siRNA-treated HEL cells infected with HCMV.
(A) Western blot demonstrating the levels of IE1-72, IE2-86, p53, and p21 in HCMV-infected HEL cells harvested at the indicated times
postinfection. (B) Western blots demonstrating levels of IE1-72, IE2-86, p53, and p21 at 16 hpi in mock-infected HEL cells (lane 1), uninfected
HEL cells pretreated with IE2-86 siRNA (lane 2), UV-treated HEL cells (lane 3), HCMV-infected HEL cells (lane 4), and HCMV-infected HEL
cells that were pretreated with siRNA (lane 5). (C) Western blots demonstrating levels of IE1-72, IE2-86, p53, and p21 at 16 hpi in mock-infected
HEL cells (lane 1), uninfected HEL cells pretreated with siRNA-Cy3 (lane 2) and IE1-72 siRNA (lane 3), HCMV-infected HEL cells (lane 4),
HCMV-infected HEL cells that were pretreated with siRNA-Cy3 (negative control) and IE1-72 siRNA (lanes 5 and 6), and UV-treated HEL cells
(lane 7).
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and zinc finger domains play important roles in the suppression
of p53 transcriptional activation.
DISCUSSION
Molecular and cytogenetic studies have provided convincing
evidence that accumulation of wild-type p53 is able not only to
inhibit proliferation but also to induce cellular apoptosis in
many types of cells (2, 34, 51). HCMV, like other DNA tumor
viruses, is able to morphologically transform cells in vitro and
stimulate host cell macromolecular synthesis in virus-infected
cells (16). Previous studies have demonstrated an increase in
p53 protein levels during HCMV infection, suggesting that p53
is targeted for regulation during HCMV infection (19, 55, 67).
Because HCMV infection activates host cell enzymes involved
in DNA replication and cellular proliferation pathways, it was
hypothesized that p53 might be specifically targeted for bind-
ing by viral proteins to activate or inactivate its apoptotic-
inducing properties. Our results demonstrate that HCMV in-
fection activates the p53 promoter as well as p53 protein
synthesis beginning at the IE stage of viral infection (Fig. 1),
supporting the previous observation that the p53 promoter
could be activated by p53 protein itself (15).
It has been demonstrated that IE2-86 can bind to and tran-
scriptionally inactivate the p53 protein (67, 70). On the other
hand, the positive effect of IE2-86 on p53 promoter activity has
been published (54). Similarly, our data presented here show
that the IE1-72 protein not only binds p53 but also inactivates
p53-dependent transcriptional activity. These results and those
from other studies (8, 54, 72) indicate that HCMV IE proteins
play important roles in p53 induction as well as transcriptional
regulation of p53 function during the IE period of HCMV
infection. The inhibitory effect of IE2-86 on p53 transcriptional
activity may be partly explained by the direct binding of IE2-86
to p53 (70). In addition, it was demonstrated that IE2-86 also
binds to mdm2 and facilitates mdm2 degradation. Thus, it can
lead to the accumulation of p53 in HCMV-infected HEL cells
(80).
Coimmunoprecipitation with anti-p53 antibody revealed
that p53 complexes with both IE1-72 and IE2-86. In the case of
IE2-86, it can bind p53 directly (3, 70) and interact with a
variety of transcription factors including TATA-binding pro-
tein (9), TFIIB (26), TAF130 (46, 47), Sp1 (46, 47), CREB
(40), and Egr-1 (76). IE2-86 binds p53 but does not abrogate
G1 checkpoint function (3). On the other hand, there has been
no previous report of direct binding between p53 and IE1-72.
In our current study, we have demonstrated that IE1-72 can be
coprecipitated with p53 (Fig. 3) and that the IE1-72 and p53
interaction might lead to the dissociation of p53 from its cog-
nitive DNA binding site, thus leading to the downregulation of
p21 expression, as shown in Fig. 7. The IE1-72 protein can
interact with the p107 protein and alleviates the transcriptional
repression of the E2F-responsive promoter (60).
The demonstration of HCMV IE1-72 inhibition of p53 bind-
ing to p53-specific DNA binding sequences with dose depen-
dency is interesting (Fig. 5A, lanes 6 to 8). The possibility of
the competition for specific DNA binding between IE1-72 and
p53 molecules can be ruled out because GST-IE1-72 alone had
no binding activity to p53-specific DNA binding sequences
(Fig. 5A, lane 5). There is no direct evidence that IE1-72,
IE2-86, and UL84 bind to the p53-responsive element. Binding
inhibition is more likely due to conformational changes of p53









FIG. 8. Exon 2/3 and the zinc finger of HCMV IE1-72 protein are required for repression of p53-dependent transactivation. (A) Schematic map
of IE1-72 full-length and deletion mutants. (B) CAT assays of lysates from p53-negative Saos-2 cells cotransfected with the expression vector for
the wild-type p53 response element pG13CAT and combinations of expression vectors for p53, IE1-72, and IE1-72 mutants, as indicated. d350-420,
mutant with a deletion of residues 350 to 420; dAcidic, mutant with a deletion of the acidic domain; WT, wild type; LZ, leucine zipper; ZF, zinc
finger.
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under similar experimental conditions, IE2-86 and UL84 en-
hanced p53 binding to p53-specific DNA sequences with dose
dependency (Fig. 5B and E, respectively). Although supershift
was observed in EMSAs as the result of the interaction of
IE2-86 and UL84 together with p53, the amount of super-
shifted product was relatively less than the nonsupershift por-
tion. The specific binding was increased comparably with in-
creases in IE2-86 and UL84 (Fig. 5B and E, respectively). The
binding enhancement by IE2-86 and UL84 may be due to a
conformational change or a modification of p53 by IE2-86 and
UL84 that enhances the p53 binding to its specific DNA se-
quences. UL84 may act as an initiator protein for viral DNA
synthesis at the origin of HCMV DNA replication (oriLyt) (57)
and interacts with IE2-86 and regulates the transactivation
activity of IE2-86 by interfering with binding of IE2-86 to its
target (13). Similar to IE2-86, Epstein-Barr virus BZLF1 di-
rectly binds p53 and inhibits its ability to activate a reporter
containing p53 binding motifs (79) but does not inhibit p53-
specific DNA binding (50).
As expected, in DNA transfection experiments IE1-72 and
IE2-86 inhibited wild-type p53 from transactivation of the p53-
responsive promoter (Fig. 6). These inhibitory effects could
again be explained by (i) IE1-72 inhibition of p53 binding to
p53-specific DNA binding sequences, as described above, and
(ii) IE2-86 enhancement of p53 binding to p53-specific DNA
binding sequences but prevention of formation of transcrip-
tionally active complexes, as suggested by previous reports (67,
70). Molecular interaction with p53 could not explain the sup-
pressive effect of p53 on the transcriptional activity because
some molecules such as apoptotic specific protein of p53 en-
hance the DNA binding and transactivator function of p53
(63). IE1-72 appears to be dominant over IE2-86 in regulating
p53 DNA binding activity (Fig. 5C), but the mechanism re-
mains to be further elucidated. As shown in Fig. 4, UL84
complexes with not only IE1 but also IE2. However, a complex
containing all three components (IE1, IE2, and UL84) was not
found (Fig. 4C). This result implied that the binding site of IE1
or IE2 to UL84 is within the common region of exon 2 and
exon 3 shared by both IE proteins. Therefore, it is likely that
UL84 only has one region for binding to exon 2 and exon 3 of
either IE1 or IE2; thus, UL84 could not bind to both IE1 and
IE2 simultaneously. To date, the functional role of each UL84-
IE1 and UL84-IE2 complex is still unclear.
Castillo et al. (8) reported that p53 protein levels increased
in fibroblasts following the expression of IE1-72 and that the
observed accumulation of p53 protein in IE1-72-expressing
cells may account for the inability of IE1-72 to induce S phase
and delay cell cycle exit. Steady-state levels of p21, which is the
indicative marker of p53 transcriptional activity, are decreased
in HCMV-infected fibroblasts, as indicated in this study (Fig.
7A) and as reported by others (10, 56). Our observation that
IE1-72 disrupts p53 binding and that IE2-86 enhances p53
binding might result in the in vivo experimental data shown in
Fig. 7 indicating that IE1-72, but not IE2-86, interacts with p53
to prevent or disrupt p53 binding to its cognitive site to down-
regulate p21 expression in the HCMV-infected cell. In cases of
either IE1-72 or IE2-86 transduction, the relative amounts of
p21 are increased (6, 65). Tanaka et al. (69) showed that p21
was increased in smooth muscle cells by IE1-72 and p53 ex-
pression. However, in the presence of high levels of p53 and
HCMV IE proteins, the HCMV-infected cells are mostly in an
active metabolic and proliferative state, depending on the cell
cycle status and cell types. Furthermore, both IE1-72 and
IE2-86 proteins can bind to different members of the retino-
blastoma protein (pRb) family to activate E2F-responsive pro-
moters and cyclin-dependent kinases. IE1-72 interacts with the
p107 protein while IE2-86 binds to pRb (8, 25, 37). IE1-72 and
IE2-86 expression can alleviate the repression of E2F tran-
scriptional activity mediated by p107 and pRb, respectively (18,
37, 60). The binding of IE1-72 to p107 displaces cyclin E/Cdk2
from p107; released cyclin E/Cdk2 is able to function as an
active kinase, but IE2-86 cannot activate the kinase activity
(81).
The IE2-86–p53 interaction did not impair epitope recogni-
tion for anti-p53 antibody with the specific site positioned
in the DNA binding domain of p53 (3). Although IE2-86
strengthens the binding of p53 to the p53-responsive element
(Fig. 5), transcriptional activity of p53 was inhibited by IE2-86
(Fig. 6). IE2-86 binds to the histone acetyltransferase domain
of the p53 coactivators, p300 and CBP (CREB-binding pro-
tein), and blocks their acetyltransferase activity on both his-
tones and p53. IE2-86 thus downregulates p53-dependent gene
activation by inhibiting p300/CBP-mediated local histone acet-
ylation (32). Therefore, the experiment on the interactions
between the oligonucleotides containing the p53-responsive
element and the purified p53 protein (shown in Fig. 5) might
not be able to explain adequately the mechanism of HCMV-
induced metabolic activation in HCMV-infected cells.
In mapping the domains of IE1-72 that are involved in sup-
pression of transcriptional activation of p53 activity, we dem-
onstrated that exons 2/3 and zinc finger domains within exon 4
of IE1-72 were responsible. In view of the fact that exons 2 and
3 are shared between IE1-72 and IE2-86 (7), it could be argued
that IE2-86 should also have a suppressive effect on p53 activ-
ity. Nevertheless, we have recently found that the leucine zip-
per domain in exon 4 of IE1-72 is needed for IE1-72 and p107
interaction (81), while in this communication we have demon-
strated that, in addition to exons 2 and 3, the zinc finger
domain is needed for IE1-72’s effect on the ability of p107 to
affect transcriptional activation of E2F (37). Thus, additional
domains other than exon 2 and exon 3 likely exist within exon
4 and exon 5 of major IE genes and may be needed for specific
interactions between IE proteins and their counterparts for
specific functions.
Exon 4 and exon 5 of HCMV IE genes are unique regions of
IE1-72 and IE2-86, respectively. Both exon 4 and exon 5 con-
tain a sequence motif called the zinc finger, with two Cys and
two His residues. The orientations of the zinc finger of IE1-72
(HX2HXFX3LX2C4C) and IE2-86 (CX4CXL5FX3HX4H) are
opposite to each other (23). The putative zinc finger of IE2-86
(from C428 to H452) is dispensable for DNA binding and
autorepression (1), and the deletion mutant of IE2-86 (dele-
tion of residues 325 to 448) containing zinc finger/LIM domain
damage has no effect on the binding to p53 (80). Such distinct
patterns of zinc finger arrangements may result in different
consequences from IE1-72 and IE2-86 interactions with p53
protein with regard to p53’s ability to bind to its specific DNA
sequences.
In conclusion, we have shown that HCMV IE1-72 and
IE2-86 can transactivate p53 promoter and are involved in the
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inhibition of p53-dependent transactivation by a possible con-
formational change in p53-DNA binding. Our data also sug-
gest that IE1-72 represses the p53 transactivation activity by a
unique binding hindrance mechanism different from that of
IE2-86. We have also demonstrated that IE1-72, rather than
IE2-86, is responsible for p21 downregulation in HCMV-in-
fected HEL cells.
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